+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
IPSC Derived NK Cells- Pipeline Insight, 2025 - Product Thumbnail Image

IPSC Derived NK Cells- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2025 - Product Thumbnail Image

Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Pheochromocytoma- Pipeline Insight, 2025 - Product Thumbnail Image

Pheochromocytoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Phaeochromocytoma - Pipeline Insight, 2025 - Product Thumbnail Image

Phaeochromocytoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
From
From
Liver Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Therapeutics - Global Strategic Business Report

  • Report
  • September 2025
  • 287 Pages
  • Global
From
From
From
Throat Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Throat Cancer Therapeutics - Global Strategic Business Report

  • Report
  • September 2025
  • 267 Pages
  • Global
From
Laryngeal Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Laryngeal Cancer Therapeutics - Global Strategic Business Report

  • Report
  • September 2025
  • 273 Pages
  • Global
From
Oral Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Oral Cancer Therapeutics - Global Strategic Business Report

  • Report
  • September 2025
  • 182 Pages
  • Global
From
Sarcoma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Sarcoma Therapeutics - Global Strategic Business Report

  • Report
  • September 2025
  • 180 Pages
  • Global
From
Soft Tissue Sarcoma - Global Strategic Business Report - Product Thumbnail Image

Soft Tissue Sarcoma - Global Strategic Business Report

  • Report
  • September 2025
  • 282 Pages
  • Global
From
Oncolytic Virotherapy - Global Strategic Business Report - Product Thumbnail Image

Oncolytic Virotherapy - Global Strategic Business Report

  • Report
  • September 2025
  • 243 Pages
  • Global
From
Gastric Cancer - Global Strategic Business Report - Product Thumbnail Image

Gastric Cancer - Global Strategic Business Report

  • Report
  • September 2025
  • 582 Pages
  • Global
From
Metastatic Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Metastatic Cancer Drugs - Global Strategic Business Report

  • Report
  • September 2025
  • 377 Pages
  • Global
From
Oncolytic Virus Immunotherapy - Global Strategic Business Report - Product Thumbnail Image

Oncolytic Virus Immunotherapy - Global Strategic Business Report

  • Report
  • September 2025
  • 383 Pages
  • Global
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more